Status: Finalised
First registered on:
25/01/2016
Last updated on:
03/04/2018
1. Study identification
EU PAS Register NumberEUPAS12194
Official titleDrug utilisation study (DUS) on flupirtine-containing medicinal products
Study title acronym
Study typeOther: Retrospective Database Analysis
Brief description of the studyRetrospective drug utilisation study using patient-level databases to characterise prescribing practices of flupirtine-containing medicinal products during routine clinical use and assess the main reasons for prescription by representative groups of prescribers before and after SmPC review
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 1 (imposed as condition of marketing authorisation)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIMS Health
Department/Research groupReal World Evidence Solutions
Organisation/affiliationIMS Health
Details of (Primary) lead investigator
Title Dr
Last name Massoud
First name Toussi
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Germany
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed26/06/201526/06/2015
Start date of data collection30/11/201530/11/2015
Start date of data analysis
Date of interim report, if expected
Date of final study report29/02/201611/11/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesHormosan100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Mrs
Last name Dombrowski
First name Silvia
Address line 1Darmstädter Landstraße 108
Address line 2
Address line 3
CityFrankfurt am Main
Postcode60598
CountryGermany
Phone number (incl. country code)49-69-66044765
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Kostev
First name Karel
Address line 1Darmstädter Landstraße 108
Address line 2
Address line 3
CityFrankfurt am Main
Postcode60598
CountryGermany
Phone number (incl. country code)49-69-66044878
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N02BG07 (flupirtine)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects10000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Disease Analyzer, Germany
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
Characterisation of prescribing practices of flupirtine-containing medicinal products during routine clinical use and assessment of the main reasons for prescriptions by representative groups of prescribers
Are there primary outcomes?Yes
Number of Flupirtine patients per specialty, per region (East/West Germany) and overall patients in the office
Patient demography (age, gender and insurance status)
Diagnoses, related to Flupirtine prescriptions
Diagnoses explicitly associated with Flupirtine prescriptions
Co-diagnoses associated with Flupirtine prescriptions
Therapies, related to Flupirtine
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Describing of Flupirtine user characteristics based on Disease Analyzer database. The validity and representativity of database is proved and displayed in publications.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
